Crocs: Double-Digit Buyback Yield (Ticker: CROX)
Crocs has $2 billion of buyback authorization, more than a third of its market cap, as North American sales stabilize and HeyDude drags on…
NASDAQ
Crocs, Inc.
CROX
15 stories
$5.7B Market cap · 2026-10-23
Barbarian Capital on X
$CROX new demand driver uncovered https://t.co/sJumnF7PRz
Negligible Capital on X
There was a small part of me that thought $CROX was going to rip yesterday after Alex Wang wore them at Meta Connect. Didn't happen. Makes me feel a little better about market froth levels https://t.co/YicRcUsEcM
Barbarian Capital on X
$CROX is the footwear for historic moments https://t.co/BWIcDcD92J
Asif Suria on X
$ONON benefiting from the $1 billion stock buyback announcement as well at their Investor Day. Thankfully they didn't have to tank the stock first by buying a company like HeyDude like $CROX did. Although at this point it looks like Crocs has done enough penance and has been absolved of its sins.
I Tested Three Cannibals Against Dillard’s. I Bought Two. (CROX, CNX, GPI)
Crocs, CNX and Group 1 are tested against Dillard’s buyback-driven share-count reduction, with Group 1 leading and CNX’s convertible notes…
Who Really Runs Crocs? The Autopsy.
Crocs CEO Andrew Rees turned around the core brand, then borrowed $2 billion for HEYDUDE, whose $737 million write-down followed wholesale…
Li Lu Bought Crocs. Follow the Free Cash Flow (CROX)
Crocs drew Li Lu’s investment after generating $660 million of 2025 free cash flow, despite the HEYDUDE write-off, tariff pressure and…
Stocks on My Radar - Consumer Edition
Crocs’ core brand surpassed $1 billion in quarterly revenue, while HEYDUDE weakness, tariffs and 2025 impairments weigh on shares trading…
Asif Suria on X
Nike's stock $NKE is down almost an additional 10% since I wrote this in June and what is even more remarkable is that On Holding $ONON is down 31% over the last year. The company went public on September 15, 2021 at $24 per share and closed its first day of trading at $35. All the wins On Running had against Nike, didn't matter because the starting valuation the market afforded the company towards the tail end of the COVID-19 bull market was too high. I have a pair of On shoes and had almost forgotten how remarkably comfortable they are until I switched to an older pair of Asics for a day. Ever since my Skechers shares were acquired by the PE firm 3G Capital last year, I have been thinking about investing in a potential turnaround at Nike or betting on $ONON's growth but thankfully decided against either option. Decker's $DECK with its HOKA and UGG brands hasn't been too hot either, down 14% over the last year. The correct move would have been $CROX or Asics in the Japanese market. But that is hindsight bias. Looking forward, two insiders, including the Co-CEO of $ONON appear to be bullish about the company's future prospects and purchased $2 million worth of stock each according to a Form 4 filed yesterday. The same insiders including the other Co-CEO also purchased shares in May at higher prices. Insiders are often early and that could certainly be the case here but these purchases are making me take a fresh look at $ONON again.
TSOH Weekly Roundup (08/07/2026)
TSOH’s weekly roundup covers Crocs’ $218.6 million Malta tax savings, Roblox’s forecast bookings decline and Lululemon’s CEO change amid…
April Earnings Update
Crocs raised 2026 EPS guidance to $13.20-$13.75 and bought back $73.6 million of stock, while Huntsman, Pitney Bowes and Alpha…
Brian McGough on X
Great day to be short $BOOT and $CROX. On Boot, the CEO leaving is a massive tell. If he believed his bull narrative, then he'd get paid more by doubling the store base than he would at ROST. I get to TAIL earnings power here of about $3.50 -- the Street is double that. If I'm right, this will be a $30-$40 stock. Still plenty of downside...
Voss Capital on X
In Voss's Q3 2023 letter we give updates on $ECN and $CROX and highlight a new long idea, $CRH (base case PT $120, 118% upside). Link here: https://t.co/iCyikUpqno https://t.co/NtFZk6UERg
Voss Capital on X
Voss's Q3 letter is out. We take a look at some macro fears that failed to materialize this year, comment on historically cheap small cap valuations, and provide brief updates on our top 4 longs ( $GFF $IMXI $EXTR $BXC) and one new core idea ( $CROX). https://t.co/qG5Mo94ORB
Investor Letters
Letters that discuss CROX.
- Patient Capital Management 3Q25 Portfolio Activity & Attribution 3Q25 PGEN $2.4BBABA $254BCROX $5.7B
- Forager Funds Management Annual Report 2025 financial year 3697 $1.7B3769 $4.5B4194 $2.5B
- Patient Capital Management 4Q24 Portfolio Activity and Attribution 4Q24 COIN $44BCROX $5.7BCVS $120B
- Baird Equity Asset Management Q2 2026 Commentary and Market Outlook Q2 2026 AAON $6.1BAGYS $3.3BALKS $7.4B
- Patient Capital Management 3Q25 Portfolio Recap 3Q25 PGEN $2.4BUNH $376B
Tickers on this page
Companies the stories above are also about, besides CROX.
